NCT01207492 2026-02-20
Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
Dana-Farber Cancer Institute
Phase 2 Completed
Clinical Trials
10 trialsNCT05349643 2024-07-05
A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT
AmMax Bio, Inc.
Phase 2 Completed
NCT04731675 2024-06-27
An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee
AmMax Bio, Inc.
Phase 2 Completed
NCT04952896 2022-11-02
Clinical Study of Magnetic Resonance Imaging and Deep Learning of Joint Synovial Disease
Peking University Third Hospital
Completed
NCT02371369 2022-05-11
ENLIVEN
Daiichi Sankyo
Phase 3 Completed
NCT02471716 2021-08-31
FPA008-002
Five Prime Therapeutics, Inc.
Phase 1/2 Completed
NCT04955535 2021-07-08
Screening of Specific Genes for Pigmented Villous Nodular Synovitis
Peking University Third Hospital
Completed
NCT03291288 2021-05-14
Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)
Daiichi Sankyo
Phase 1 Completed
NCT01643850 2021-01-05
MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)
Novartis
Phase 2 Completed
NCT01261429 2013-04-16
Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT)
Centre Leon Berard
Phase 2 Completed